the new generation glocalized network in theragenomic and personalized medicine and the genetics of patient's individualized drug safety
February 16, 2017 – The American Food & Drug Administration (FDA)Â just approved Brodalumab (Siliq) to treat adults with moderate-to-severe plaque psoriasis. Brodalumab (Siliq) is administered as an injection. Brodalumab (Siliq)Â is intended for patients who are candidates for systemic therapy (treatment …
Brodalumab (Siliq) with a fatal touch: New psoriasis drug approved Read more »
 June 22, 2016 – The European Medicines Agency (EMA) has approved, as of the end of May 2016, Infliximab (Flixabi). Infliximab (Flixabi) is a monoclonal antibody that has been designed to attach to a protein called tumour necrosis factor-alpha (TNF-alpha) and block …
Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF JAMA Dermatol 2016 Apr; PMID: 27120802 Abstract Importance: Psoriasis has been shown to be associated with overweight and type 2 diabetes mellitus. The genetic association is unclear. Objective: …
Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity Read more »
April 11, 2015 – Dutch clinicians report what they believe is the first case of progressive multifocal leukoencephalopathy (PML) after treatment with compounded dimethyl fumarate (DMF) in a patient without severe lymphocytopenia. This situation was “previously thought to be unlikely,” Dennis …
January 21, 2015 –Â On this day, the U.S. Food and Drug Administration has approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis. Â Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is an …